Yishengukang Decoction for strengthening the healthy, detoxifying and removing blood stasis in the treatment of cancerous somatic pain:A Multi-Center Randomized Controlled Trial
- Conditions
- Carcinomatous somatic pain
- Registration Number
- ITMCTR2100004499
- Lead Sponsor
- Qinglin Zhang
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1) Aged 18-80 years;
2) Accordance with the diagnostic criteria of Western medicine for carcinomatous somatic pain;
3) TCM syndrome differentiation belongs to kidney deficiency and (or) stagnation of blood stasis and toxin;
4) NRS > 3 for moderate to severe cancer somatic pain;
5) KPS > 30;
6) The expected survival time Will be more than 3 months;
7) Voluntarily accept the study and sign the letter of understanding.
1) Radiotherapy, chemotherapy or nerve block therapy were applied to the affected or painful part of the tumor within 1 month before the beginning of the observation period;
2) Non cancerous pain, as if accompanied by tumor emergency related pain, tumor related other neuropathic pain;
3) Have a history of drug abuse or addiction;
4) Allergic to the test drug;
5) Patients with severe organ dysfunction;
6) Those who can't cooperate with the treatment plan and can't evaluate their pain and general condition.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method RS;
- Secondary Outcome Measures
Name Time Method SRE;KPS score;QLQ-C30;Frequency of pain outbreaks;